Clinical trials, brain imaging, biomarkers, and intervention studies drew more than 4,000 researchers to the Alzheimer's Association International Conference 2014 at the Copenhagen Congress Center in Demark. Data from Phase 2 clinical trials of crenezumab, an anti-Aβ antibody, disappointed, but positive results from a large Finish intervention study raised hope that lifestyle changes can pay dividends toward preventing dementia. The Alzheimer's Prevention Initiative announced a new partnership with Novartis to test if an active Aβ vaccine or a BACE inhibitor can slow or prevent sporadic Alzheimer's in people who are genetically predisposed to the disease. Abstracts for the meeting are freely available here.
Novartis Pharmaceuticals Corporation will partner with the Banner Alzheimer's Institute testing experimental preclinical therapies in the upcoming Alzheimer's Prevention Initiative ApoE4 study. The study complements the API ADAD trial.
At AAIC 2014, crenezumab Phase 2 trial results stirred debate.
Researchers are looking to the eye for a cheap, easy way to detect Alzheimer’s pathology in the brain.
Could tweaking methodologies improve amyloid diagnosis and tracking?
A mouse study testing the combined effects of a BACE inhibitor and plaque-clearing antibody builds new support for a combination strategy aimed at reducing Aβ buildup in people.
A global effort to combat dementia has been conducting a yearlong series of events. Alzforum spoke with Dennis Gillings, who chairs the new World Dementia Council.
New data strengthens the evidence that dementia risk is dropping in developed countries, possibly due to better education and heart health.
Lifestyle changes to evade dementia, such as healthy eating and exercise, made a strong showing at the Alzheimer’s Association International Conference in Copenhagen, Denmark.
Could exosomes—tiny parcels extruded from cells—make for a blood-based Alzheimer’s marker?
An active immunotherapy is coming to the fore as researchers continue to try novel therapies.
Does a tau-based early diagnosis look more likely?
Researchers continue to screen blood for factors that signal neurodegenerative disease.
Researchers are ramping up efforts to target tau for Alzheimer’s and other tauopathies.